Daclatasvir

Janessa M. Smith, PharmD, BCPS
Daclatasvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
    • Daclatasvir is indicated for treatment of HIV/HCV co-infected patients, in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis and in patients that develop recurrent HCV post-transplant.

NON-FDA APPROVED USES

Treatment of HCV genotypes 2, 4.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: August 1, 2016